Raptor Pharmaceuticals Corp. (Nasdaq: RPTP) reported positive interim results from a Phase 2/3 clinical trial of its Huntington's Disease treatment RP103 sending the stock price soaring $2.22 to close at $17.14.
Raptor Pharmaceuticals Reports Upbeat Interim Trial Results
February 20, 2014 at 16:02 PM EST
